Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. März 2026 07:30 ET | Quelle: EDAP TMS S.A.

EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026

EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026 Company to host conference call and webcast on Wednesday, March 25 at 8:30 a.m. EDT AUSTIN, Texas, March 4,...
03. März 2026 09:32 ET | Quelle: Research and Markets

Prostate Cancer Market Competitive Landscape Report 2026: Comprehensive Insights About 230+ Companies and 265+ Drugs by Product Type, Stage, and Route of Administration

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Prostate Cancer - Competitive Landscape, 2026" report has been added to ResearchAndMarkets.com's offering.This "Prostate Cancer - Competitive...
26. Februar 2026 10:14 ET | Quelle: American Urological Association

AUA Announces Updates to the Early Detection of Prostate Cancer Guideline

BALTIMORE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2026 amendment to the Early...
26. Februar 2026 10:00 ET | Quelle: Curium

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE...
24. Februar 2026 09:00 ET | Quelle: Myriad Genetics, Inc.

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

Data presented at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests.
19. Februar 2026 21:40 ET | Quelle: Candel Therapeutics

Candel Therapeutics Announces Pricing of Public Offering

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
19. Februar 2026 16:05 ET | Quelle: Candel Therapeutics

Candel Therapeutics Announces Proposed $100 Million Public Offering

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
19. Februar 2026 16:01 ET | Quelle: Candel Therapeutics

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized...
12. Februar 2026 16:30 ET | Quelle: Profound Medical Corp.

Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative...
12. Februar 2026 08:30 ET | Quelle: Profound Medical Corp.

Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is...

Nächste Seite